Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on CLINIGEN GROUP PLC. We currently have 34 research reports from 3 professional analysts.
|16Mar17 07:00||RNS||Launch of a European Patient Access programme|
|15Mar17 07:00||RNS||Half-year Report|
|09Mar17 08:58||RNS||Holding(s) in Company|
|22Feb17 09:00||RNS||Notification of half year results date|
|25Jan17 07:00||RNS||HY trading update|
|13Jan17 10:00||RNS||Change of Joint Broker|
|14Nov16 09:44||RNS||Director/PDMR Shareholding|
Frequency of research reports
Research reports on
CLINIGEN GROUP PLC
CLINIGEN GROUP PLC
N+1 Singer - Clinigen Group - In line interims, outlook positive
15 Mar 17
No surprises from Clinigen this morning, with interims as expected and no change to forecasts. Growth is being generated across all divisions, with a particularly strong performance from Link and Clinical Trial Services. We stay positive and see multiple growth opportunities, both organic and acquisitive in the periods ahead. The only slight disappointment is around the Article 31 restrictions of Cardioxane, where timing looks to have slipped. This was not in our estimates, but was hoped for shortly. We would view any weakness as a buying opportunity.
N+1 Singer - Clinigen Group - In line H1 update
25 Jan 17
A solid H1 update with the promise of more good news to come. Trading is reported to be in line, helped by FX benefits and a strong organic performance, particularly from CTS. We leave our PBT/EPS forecasts unchanged for now, but see upside potential from M&A and further organic growth potential in SP in particular. Remain at Buy with a 895p TP.
N+1 Singer - Morning Song 25-01-2017
25 Jan 17
Applied Graphene Materials (AGM LN) Board and operational appointments | Centaur Media (CAU LN) Trading update provides reassurance | Clinigen Group (CLIN LN) In line H1 update | Eckoh (ECK LN) Significant contract win via Capita partnership | Restaurant Group (RTN LN) Mixed YE update with further downgrades | StatPro Group (SOG LN) Full year revenue and profits in line
Small Cap Breakfast
25 Jan 17
Impact healthcare REIT— Intends to float on the main market. Seeks to raise £160m to acquire a portfolio of up to 58 care homes. Expected Admission 7 March. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January 2017.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - EKF Diagnostics - Final results & potential buy back
20 Mar 17
FY16 prelims are slightly ahead of our latest expectations, those having been increased materially over the course of H2’16 as the strength of the recovery in trading became apparent. In order to maximise shareholder value, the directors are currently examining a potential break up of the group. This would also involve a delisting from AIM. A buy back offer at 21.5p would therefore be made to those investors that wish to exit now rather than holding their shares for the two years plus it would likely take to achieve a potentially higher realisation value for the businesses.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Good results, but further restructuring complex for investors
20 Mar 17
EKF Diagnostics FY 2016 results are slightly ahead of expectations, with both higher revenue and better EBITDA. Management has also announced plans to split the company into two separate companies, Point of Care and Laboratory Diagnostics, with the prospect of a delisting to manage the process. The primary metric for valuation of the two businesses is different consequently we believe that the separation is likely to generate significant value. However, in anticipation of the volatility likely given the restructuring announced this morning, despite the strength of the results, we reduce our recommendation to HOLD and maintain our 21p target price.